|Bid||6,345.00 x 200|
|Ask||6,351.00 x 34100|
|Day's Range||6,329.00 - 6,370.00|
|52 Week Range||61.35 - 6,370.00|
|PE Ratio (TTM)||81,423.08|
|Dividend & Yield||1.36 (7.11%)|
|1y Target Est||N/A|
Citigroup cut its rating for the struggling generic drug maker to 'neutral'.
JERUSALEM/LONDON/FRANKFURT, Aug 16 (Reuters) - Teva Pharmaceutical Industries is looking to team up with other drugmakers to fund some of its development pipeline as it struggles with debts and expiring patents. "We are looking for partners ... a series of partners.
Teva Pharmaceutical Industries said on Wednesday it was looking into a series of partnerships to fund some projects in its drug development pipeline, as the drugmaker seeks to pay down more than $5 billion of debt this year.